Tvardi Therapeutics Updates on TTI-101 Clinical Trial Progress
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jan 08 2026
0mins
Tvardi Therapeutics provided further updates from its Phase 2 REVERT IPF clinical trial of TTI-101 in idiopathic pulmonary fibrosis, IPF. Preliminary results were announced on October 13, 2025. Additional analysis was conducted to interrogate the impact of STAT3 inhibition using TTI-101 on fibrosis, inflammatory markers and pulmonary function. In order to do so, the additional analysis was limited to patients who were exposed to study drug for 12 weeks. Upon interrogation of pharmacokinetics and adverse events, one patient was removed from the analysis due to receiving less than 60% of the expected dosing; two patients were removed due to no measurable TTI-101 observed in the blood as well as no reported adverse events; and one additional patient was removed as an outlier for the 12-week analysis as their pulmonary function initially improved on treatment, but was subsequently severely impacted by acute bronchitis deemed unrelated to study drug. This resulted in a dataset of 40 patients analyzed: 16 pooled patients treated with TTI-101, and 24 patients treated with placebo.
Get Free Real-Time Notifications for Any Stock
Monitor tickers like TVRD with instant alerts to capture every critical market movement.
Sign up for free to build your custom watchlist and receive professional-grade stock notifications.
Analyst Views on TVRD
Wall Street analysts forecast TVRD stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for TVRD is 9.00 USD with a low forecast of 4.00 USD and a high forecast of 15.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
6 Analyst Rating
2 Buy
4 Hold
0 Sell
Moderate Buy
Current: 4.060
Low
4.00
Averages
9.00
High
15.00
Current: 4.060
Low
4.00
Averages
9.00
High
15.00
About TVRD
Tvardi Therapeutics, Inc., formerly Cara Therapeutics, Inc., is a clinical-stage biopharmaceutical company focused on the development of novel, oral, small molecule therapies targeting (STAT3) to treat fibrosis-driven diseases with significant unmet need. STAT3 is a central mediator across critical fibrotic signaling pathways that drive uncontrolled deposition, proliferation, survival and immune suppression. STAT3 is also positioned at the intersection of many signaling pathways integral to the survival and immune evasion of cancer cells. Its product candidate, TTI-101, is in Phase 2 clinical development for the treatment of fibrosis-driven diseases, with an initial focus on idiopathic pulmonary fibrosis (IPF), and hepatocellular carcinoma (HCC). Its second product candidate, TTI-109, is an oral, small-molecule, which is structurally related to, yet chemically distinct from, TTI-101 and is designed to enhance the ability to target STAT3.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Tvardi to Present TTI-101 Clinical Data at 44th J.P. Morgan Healthcare Conference
- Clinical Trial Progress: Tvardi Therapeutics will present new Phase 2 REVERT IPF clinical trial data for TTI-101 at the 44th J.P. Morgan Healthcare Conference on January 15, 2026, demonstrating encouraging signals across fibrosis, inflammatory markers, and pulmonary function, further supporting TTI-101's efficacy in inhibiting STAT3.
- Market Demand Alignment: TTI-101, an innovative therapy targeting fibrosis-driven diseases, addresses the urgent need for effective treatment options in the clinical landscape, potentially bolstering the company's market position in the biopharmaceutical sector.
- Investor Engagement: The conference will provide a webcast for investors to access detailed information about TTI-101, likely attracting increased investor interest in Tvardi's clinical advancements and future potential.
- Strategic Positioning: Tvardi's focus on developing small molecule therapies targeting STAT3 highlights its strategic importance in addressing unmet medical needs in fibrosis diseases, which may present long-term growth opportunities for the company.
Continue Reading
Tvardi Therapeutics Shares Plunge 80% Following Disappointing Phase 2 Trial Data
- Stock Plunge: Tvardi Therapeutics experienced an over 80% drop in share price on October 13, 2025, following disappointing preliminary data from its Phase 2 REVERT clinical trial, which is likely to severely impact investor confidence and may lead to further legal actions.
- Trial Failure: The trial aimed to assess the safety and efficacy of TTI-101 in patients with idiopathic pulmonary fibrosis, but preliminary results indicated that it did not meet its goals, potentially affecting the company's future R&D direction and funding inflow.
- Investor Losses: Faruqi & Faruqi LLP is investigating potential claims against Tvardi, encouraging investors who suffered significant losses to reach out, highlighting the legal risks that could exacerbate the financial pressures faced by the company.
- Market Reaction: The poor clinical trial results may lead to substantial losses for Tvardi's shareholders, further impacting the company's reputation and market position within the biopharmaceutical industry.
Continue Reading